BeiGene
BGNE
#881
Rank
HK$178.75 B
Marketcap
HK$1,597
Share price
-0.65%
Change (1 day)
2.73%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Net assets

Net assets on the balance sheet as of June 2024 : HK$26.16 Billion

According to BeiGene 's latest financial reports the company has HK$26.16 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

BeiGene - Net assets on balance sheet (from 2014 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$HK$27.62 B-19.33%
2022-12-31$HK$34.24 B-28.38%
2021-12-31$HK$47.81 B59.42%
2020-12-31$HK$29.99 B293.66%
2019-12-31$HK$7.61 B-44.52%
2018-12-31$HK$13.73 B156.88%
2017-12-31$HK$5.34 B95.34%
2016-12-31$HK$2.73 B375.09%
2015-12-31$HK$0.57 B188.2%
2014-12-31$HK$0.19 B-166.56%
2013-12-31$-HK$0.31 Billion

Net assets for similar companies or competitors

Company Net assets differencediff. Country
HK$46.76 M-99.82%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$10.84 B-58.55%๐Ÿ‡บ๐Ÿ‡ธ USA